Introduction
============

Methicillin-resistant *Staphylococcus aureus* (MRSA) has become a major cause of hospital-associated infection since it was first discovered in Britain in the 1960s soon after the beta-lactam methicillin was introduced for clinical use against *Staphylococci*.[@b1-idr-9-035] The emergence of MRSA infection has had a negative impact on hospital costs, resulting in longer hospital stays as well as morbidity and mortality.[@b2-idr-9-035],[@b3-idr-9-035]

MRSA colonization is a major risk factor for subsequent MRSA infection.[@b4-idr-9-035],[@b5-idr-9-035] In the USA and Singapore, studies found that 8.5% and 15% of MRSA-colonized patients, respectively, developed MRSA infection over subsequent years.[@b4-idr-9-035],[@b5-idr-9-035] The presence of MRSA at multiple sites strongly predicts development of MRSA infection.[@b6-idr-9-035],[@b7-idr-9-035] Colonized patients are an important reservoir of MRSA in hospitals, and diagnostic clinical samples can miss \~35%--84% of these colonized patients.[@b8-idr-9-035],[@b9-idr-9-035]

There is no general consensus on effective control measures and the optimum anatomical swabbing sites, which are least costly, for use as an infection control measure for MRSA.[@b9-idr-9-035] Studies have been devised to determine the optimal site or combination of sites for detection of MRSA colonization. Issues of detection method, cost, efficiency, accuracy, and study design have been considered. Different countries have different policies on the number of sites for screening of MRSA colonization for optimum results. In the USA, nasal swabbing as the single site is recommended while in the UK, at least two sites are recommended.[@b9-idr-9-035]--[@b11-idr-9-035]

Bacteremia surveillance has been used as a passive method for measuring effectiveness of MRSA control methods, but this has a disadvantage of requiring long follow-up to determine whether infection control interventions have had an effect in a hospital.[@b12-idr-9-035] There is a need to evaluate other surveillance measures to achieve optimum control of MRSA.[@b13-idr-9-035] Our study is aimed at establishing the significance of MRSA isolation from different sites suspected of colonization as a surveillance measure.

Methods
=======

Selection of articles for inclusion
-----------------------------------

Candidate articles were selected for the reference document, first on the basis of title, and then on reading the abstract. All candidate articles were retrieved before final selection. The articles qualified for selection for review if they met the following criteria: 1) original research written in English and published in a peer-reviewed journal; 2) explicit information on MRSA colonization sites; and 3) any article published after 1966 providing data on culture isolates of MRSA at both nasal and extra-nasal and results were available.

Focus of the study
------------------

The focus of this study was, primarily, to analyze MRSA colonization sites or multiple MRSA colonization sites as a method of MRSA detection.

Literature search
-----------------

The study was based on an updated literature search in Medline. The search terms were: "MRSA surveillance", "Methicillin-resistant *Staphylococcus aureus* surveillance", "MRSA", "colonization site", ("Screening" OR Swab OR surveillance AND MRSA). The database search was supplemented by a bibliographic search in previous reviews in the field. The authors read all the abstracts to retrieve relevant articles, minimizing the possibility of selective selection.

Data extraction
---------------

The data extracted from each of the included studies consisted of the first author; year of publication; study design; country and period of the study; number of patients and/or isolates of MRSA; and the type of the culture specimen for MRSA, the site of MRSA isolation, and the percentage sensitivity of the MRSA isolates at each site in relation to the total sites.

Results
=======

We reviewed 3,211 abstracts and 177 manuscripts, and 160 were excluded either due to the fact that the swabbing data were only from nasal sites or that the study population were mostly children. Seventeen full articles met the criteria for analysis as they had data on screening of both nasal and extra-nasal sites of adults at admission ([Table 1](#t1-idr-9-035){ref-type="table"}).[@b14-idr-9-035]--[@b30-idr-9-035] The studies included for analysis were conducted between 1996 and 2014 (n=52,642 patients). Seven of the studies were conducted in South America, six in Europe, four in Asia, and none in Africa. Seven studies had study population from general wards, six from intensive care unit (ICU), and three from both ICU and general wards, while one was conducted on ward and outpatients. Eleven studies were prospectively while six were retrospectively done. Out of the 17 studies, 16 of them used directly plated MRSA culture media and one used both directly plated MRSA culture media and broth-enriched culture media. MRSA isolates were confirmed by disc diffusion assay in 16 studies, and in one study MRSA isolates were confirmed by both disc diffusion and molecular assays. Four studies had low MRSA prevalence of less than 6% (1.3%--4.1%), while the prevalence of MRSA in nine studies were high at ≥6% (6%--25%), and four studies did not state the prevalence of MRSA.

Fifteen of the 17 studies had nasal MRSA detection of less than 90% as a single area of MRSA colonization and the MRSA detection ranged from 34% to 89.7%, and only two of the 15 studies had MRSA nasal sensitivity of ≥90% as a single area of MRSA colonization.[@b24-idr-9-035],[@b25-idr-9-035] The single-site screening of nares showed low MRSA in endemic areas[@b15-idr-9-035],[@b19-idr-9-035],[@b25-idr-9-035],[@b27-idr-9-035] due to a high proportion of MRSA detected by nasal screening of 75.1% with a range of (65%--90%) ([Table 2](#t2-idr-9-035){ref-type="table"}). Nasal colonization showed MRSA detection sensitivity of less than 50% (34%--48%) in three studies.[@b16-idr-9-035],[@b21-idr-9-035],[@b29-idr-9-035]

Seven studies showed less than 90% MRSA detection sensitivity when nasal MRSA colonization was combined with one extra-nasal site.[@b14-idr-9-035],[@b16-idr-9-035],[@b19-idr-9-035],[@b20-idr-9-035],[@b23-idr-9-035],[@b29-idr-9-035],[@b30-idr-9-035] Four studies had nasal/throat; five studies nasal or throat/groin; three studies had nasal/rectum; and one study had nasal/skin or wound as best two combinations for MRSA detection sensitivity. Four studies had nasal/throat/groin; three studies had nasal/throat/rectum; while each of the two single studies had nasal/axilla/rectum and nasal/wound/perineum, respectively, as three best combinations for MRSA detection sensitivity ([Table 1](#t1-idr-9-035){ref-type="table"}). Detection of MRSA colonization was enhanced by using broth-enriched culture media and performing molecular assay, and this helped in rapid detection and identification of MRSA from mixed flora samples.[@b20-idr-9-035],[@b22-idr-9-035]

Discussion
==========

Colonized patients are important reservoir of MRSA in hospitals, and diagnostic clinical samples can miss \~35%--84% of these colonized patients.[@b8-idr-9-035],[@b9-idr-9-035] The level of endemicity of MRSA determines the kind of screening program needed in order not to miss occult carriers of MRSA and, therefore, increase cross transmission of MRSA hospital infection.[@b19-idr-9-035],[@b25-idr-9-035],[@b26-idr-9-035] The importance of doing the MRSA colonization screening has been marred with issues of cost-benefit analysis and the indication for it.[@b19-idr-9-035],[@b22-idr-9-035],[@b27-idr-9-035] Various countries have different policies on the number of sites for screening of MRSA colonization with optimum results.

Prevalence of MRSA colonization is not the same on different sites of patients' body, such as the axilla, hairline, groin, nose, perineum, rectum, throat, skin breakdown areas, eyes, and vagina.[@b14-idr-9-035]--[@b30-idr-9-035] The throat and nares show higher colonization detection as single sites ranging from 50.5% to 89.7%.[@b14-idr-9-035]--[@b20-idr-9-035],[@b22-idr-9-035]--[@b28-idr-9-035],[@b30-idr-9-035] The two studies that showed ≥90% nasal MRSA colonization sensitivity as single site still needed extra-nasal combination to have required Negative Predictive Value of MRSA detection.[@b24-idr-9-035],[@b25-idr-9-035] Single-site screening such as the nasal cavity is optimal for endemic areas with low MRSA prevalence,[@b15-idr-9-035],[@b19-idr-9-035],[@b25-idr-9-035],[@b27-idr-9-035] and this single site is likely to miss significant detection of MRSA colonization in high-risk population.[@b14-idr-9-035]--[@b16-idr-9-035],[@b21-idr-9-035],[@b29-idr-9-035] The nasal cavity as a single site for detection of MRSA colonization was not able to meet MRSA detection of ≥90% in 15 of the 17 studies under review.[@b14-idr-9-035]--[@b23-idr-9-035],[@b26-idr-9-035]--[@b30-idr-9-035] The study by El-Bouri[@b14-idr-9-035] found 50% of two swab combinations were better than single nasal swabbing and 25% were likely missed by using nasal swabbing alone. This was also found in studies by Mertz et al and Bignardi and Lowes.[@b31-idr-9-035]--[@b34-idr-9-035]

Combination swabs from two sites improved MRSA detection rate to 50% with best combination being that of nasal or throat/groin,[@b18-idr-9-035],[@b22-idr-9-035],[@b24-idr-9-035],[@b28-idr-9-035] followed by nasal/rectum or perineum.[@b15-idr-9-035],[@b17-idr-9-035],[@b21-idr-9-035]

A three-site combination improved detection rate to 99% with the best combination being that of nasal/throat/groin or perineum or rectum.[@b14-idr-9-035],[@b16-idr-9-035],[@b19-idr-9-035],[@b20-idr-9-035],[@b28-idr-9-035],[@b30-idr-9-035] In another study, the three-site combination did not reach the ≥90% sensitivity,[@b23-idr-9-035] though the overall MRSA colonization at any site was 12.2% (1.3%--24%), and this could be due to a variation in the MRSA detection method. Nasal colonization was 47.6% (22.2%--87%), nasal plus one extra-nasal combination was 89.6% (62.5%--100%), and nasal plus two extra-nasal sites combination was 94.2% (81%--100%), as shown in [Table 2](#t2-idr-9-035){ref-type="table"}. Similar findings were reported in a systematic review conducted by McKinnell et al.[@b31-idr-9-035]

Most of the studies under review for extra-nasal screening were done in developed countries of USA, Europe, and Asia even though many studies have indicated the prevalence of MRSA in countries of Africa. Apart from level of endemicity, cost-benefit analysis has been mainly put under consideration when it comes to either using nasal swabbing alone or combination of extra-nasal sites.[@b15-idr-9-035],[@b32-idr-9-035],[@b35-idr-9-035] Another issue is to do with acceptability of the method of swabbing at certain sites, like throat and perineum, by the study population.[@b15-idr-9-035],[@b27-idr-9-035],[@b36-idr-9-035]--[@b39-idr-9-035] Some studies found that throat swabbing was better at MRSA detection than nasal swabbing.[@b14-idr-9-035],[@b16-idr-9-035],[@b27-idr-9-035],[@b36-idr-9-035]--[@b39-idr-9-035] Fifteen of the 17 studies (88%) reviewed favored inclusion of extra-nasal swabbing for the detection of MRSA colonization. Two studies under review showed that the method of MRSA detection has effect on the detection of MRSA at different sites.[@b20-idr-9-035],[@b22-idr-9-035] Lauderdale et al[@b20-idr-9-035] found that direct culture method missed \~50% detection rate of MRSA from nasal swabbing as compared to broth-enriched medium. Broth-enriched culture improved detection rate of MRSA by 24% in swabs from the throat, axilla, and perineum. These results concurred with those of Grmek-Kosnik et al and Nonhoff et al.[@b40-idr-9-035],[@b41-idr-9-035] The variation in the detection rate at different sites could also be attributed to MRSA load and method of detection and decolonization procedures.[@b23-idr-9-035],[@b42-idr-9-035] The association was not seen in the study by Baker et al,[@b23-idr-9-035] where it was found that the strongest predictor of extra-nasal colonization was nasal colonization and not broth-enriched medium. Currie et al[@b15-idr-9-035] found that the sensitivity of rectal swabs increased from 59% to 67% for MRSA-Select plates when mannitol-salt agar (MSA-OX) with 4 mg/L oxacillin culture was used, but there was no significant change in sensitivities of nasal and open-skin-site swabs with MSA-OX culture. Use of PCR methods did not show any significant difference in the detection of MRSA.[@b23-idr-9-035] The anatomical sites to be swabbed also have an effect on the culture results due to the fact that participants may decline to give consent, due to psycho-social stigma associated with very private or anatomically sensitive areas of the body to be swabbed. The throat or posterior pharynx, perineum, and rectum are likely to limit the sites available for access due to increased number of participants declining to give consent to swabbing, thus leading to discrepancy of results.[@b22-idr-9-035],[@b23-idr-9-035]

Conclusion
==========

We concur with previous published findings based on localized research analysis. Our systemic review of 52,642 cases indicates that a combination of three swabs from different sites provided the highest detection rate of MRSA colonization. The use of three swab sites is likely to improve recognition and treatment of MRSA, which may in turn reduce infection and transmission to other patients in hospital despite associated incremental costs.

Recommendation
==============

The prevalence of MRSA carriage plays an important role in strategies used to manage colonization. The decision on the optimal sampling sites for MRSA detection should be determined by the goal of the intervention. If the intention is eradication in low-prevalence, MRSA-colonized populations, prospective surveillance and infection control should be re-enforced. For reduction in high-prevalence settings, prospective surveillance should be considered with universal screening.
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###### 

Participants, bacteriological testing, and outcomes of MRSA testing for identification of sites of MRSA colonization

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author name, country                            Period of study               Study design                MRSA detection method                                                                                      Swabbing method and site                                                                                         Study population and size                                                     MRSA positive number (%)                                       MRSA site colonization   Best site combination                                                                                                                                                                     
  ----------------------------------------------- ----------------------------- --------------------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------- -------------------------------------------------------------- ------------------------ ----------------------- ------------------------------------------------------------------------------- --------------------------------------------------------------------------------- ---------------------------------------
  El-Bouri and El-Bouri,[@b14-idr-9-035] Wales    January 2010--November 2012   Retrospective               Chromogenic MRSA medium/Columbia blood agar                                                                Only simultaneously swabbed patients of all anatomical sites were accepted                                       Adults at high risk for MRSA due to frequent re-admission or others (4,769)   925/4,769 (19.4%)                                              467/925 (50.5%)          458/925 (49.5%)         365 (39.5%)                                                                     Throat/groin 74.5% (71.7--77.3)\                                                  Throat/nose/groin 92% (90.1--93.6)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Nose/groin 72.1% (69.2--75)                                                       Nose/throat/perineum 91% (88.9--92.7)

  Currie et al,[@b15-idr-9-035] Canada            January 2004--June 2007       Descriptive analysis        MSA-OX, MSA-FOX, MRSA-Select                                                                               First set of screening swabs                                                                                     All surgical and medical patient with HA-MRSA risk factors (23,365)           627/2,3365 (2.7%)                                              419/627 (66.8%)          208/627 (33.1%)         160 (34%)                                                                       Nares/rectum 586/612 (96% 94--98)                                                 

  Jang et al,[@b16-idr-9-035] Republic of Korea   March 2010--February 2011     Prospective observational   BBL™ CHROMagar™ MRSA medium                                                                                Swabbed at the time of admission, 48 hours after admission, and then weekly                                      Adult patients (282)                                                          59/282 (21%)                                                   20/59 (34%)              39/59 (66.1%)           66%                                                                             Nasal/throat 50/59 (84.7%)                                                        Nasal/throat/rectum (94.9%)

  Yang et al,[@b17-idr-9-035] USA                 February 2005--October 2007   Prospectively               MSA-OX                                                                                                     Swabbing once at anatomic sites in MRSA infected patients                                                        Adults with SSTIs (117)                                                                                                                      48/71 (67%)              23/71 (32.4%)           17/71 (24%)                                                                     Nasal/inguinal (96%)                                                              

  Datta et al,[@b18-idr-9-035] India              January 2009--June 2010       Active surveillance         Blood agar and Mac Conkey agar and disc diffusion test using 30 ug cefoxitin disc on Mueller Hinton agar   Single anatomic swabbing                                                                                         Adults in ICU (400)                                                           90/400 (22.5%)                                                 70/90 (77.8%)            20/90 (22.2%)           11 (12.2%)                                                                      Nose/throat 86/90 (95.5%), Throat/groin 84/90 (93.3%), Nose/groin 82/90 (91.1%)   

  Girou et al,[@b19-idr-9-035] France             1993--1996                    Prospective                 Chapman agar                                                                                               Swab from nasal, perineum, and axilla at admission and once a week                                               High-risk patients from MICU (3,686)                                          150/3,686 (4.1%)                                               35/45 (78.5%)            16/45 (35.6%)           5/45 (11%)                                                                      Nasal/perineum (88.9%)                                                            Nasal/throat/perineum (98%)

  Lauderdale et al,[@b20-idr-9-035] Taiwan        August 2005--February 2006    Retrospective               Sheep blood agar (SBA) and CHROM agar MRSA and broth-enriched culture                                      Swab sample set of nose, throat or sputum, axilla, and perineum within 24 hours admission                        Patients on admission to a medical and surgicaI ICU (650)                     65/650 (10%) Direct culture (157/650 \[24%\] broth-enriched)   114/157 (72.6%)          43/157 (27.3%)          27 (17.2%)                                                                      Nasal/throat 134/157 (85.4%)                                                      Nasal/throat/perineum 146/157 (93.2%)

  Eveillard et al,[@b21-idr-9-035] France         July 2002--June 2003          Prospective                 Mannitol salt agar (MSA-Ofloxacin)                                                                         Screen swab at different anatomic sites on admission and also clinical sample and TID calculated                 1,250 from ICU and other wards                                                123/1,250 (9.8%)                                               53/123 (43.1%)           70/123 (56.9%)          54.3%                                                                           Nose/rectum (91.9%)                                                               Nose/axilla/rectum (100%)

  Hombach et al,[@b22-idr-9-035] Switzerland      August 2007--August 2008      Prospective                 BD GeneOhm™ MRSA Assay, the Xpert™ MRSA assay and broth-enriched culture                                   Swabs from different sites on admission from MRSA high-risk patients                                             425                                                                           29/425 (6.8%)                                                  26/29 (89.7%)            22/29 (76%)             ≤1                                                                              Nose/groin (100%)                                                                 

  Baker et al,[@b23-idr-9-035] USA                October 2008--February 2009   Prospective                 Chromogenic agar plate                                                                                     Swabs from acute care patients within 36 hours of admission                                                      150                                                                           16/150 (10.7%)                                                 9/16 (56.2%)             6/16 (37.5%)            3 (2%)                                                                          Nasal/oropharynx (62.5%)                                                          Nasal/oropharynx/perineum (81%)

  Mermel et al,[@b24-idr-9-035] USA               September 2007--March 2008    Retrospective               MRSA-selective chromogenic medium and sheep blood agar                                                     Adults inpatients previously identified as MRSA positive during the year prior to enrollment                     53                                                                            Not stated                                                     48/53 (91%)              40/53 (75.5%)           Similar sensitivity but combined samples increasing negative predictive value   Nares/groin (98%)                                                                 

  Fishbain et al,[@b25-idr-9-035] USA             August--November 2000         Prospective surveillance    5% sheep agar and MRSA screen agar                                                                         Adults on admission, swabs within 48 hours from both nares and both axilla                                       535                                                                           20/535 (3.7%)                                                  18/20 (90%)              5/20 (25%)              Similar sensitivity but combined samples increasing negative predictive value   Nasal/axillary (100%)                                                             

  Lucet et al,[@b26-idr-9-035] France             July 1997--December 1997      Prospective multicenter     Various media according to center                                                                          Adults in ICU swabs within 24 hours admission from nose and skin (both axilla and groin)                         2,347                                                                         162/2,347 (6.9%)                                               126/162 (77.8%)          72/162 (44.4%)          19/162 (7.2%)                                                                   Nasal/skin 148/162 (92%)                                                          

  Papia et al,[@b27-idr-9-035] Canada             May 1996--May 1997            Case control                Mannitol agar                                                                                              Swabs from adults in acute care ward from different sites                                                        1,742                                                                         23/1,742 (1.3%)                                                15/23 (65.2%)            13/23 (56.5%)           6/23 (26.1%)                                                                    Nasal/wound (91.3%)                                                               Nasal/wound/perineum (95.7%)

  Lautenbach et al,[@b28-idr-9-035] USA           January 2008--May 2008        Cross-section               ChromAgar                                                                                                  Swabs on admission by research nurse and self on admission from different sites                                  56                                                                            Not stated                                                     46/55 (84%)              48/55 (87%)             3/55 (5.5%)                                                                     Nares/throat 50/55 (91%)                                                          Nares/throat/groin (98%)

  Senn et al,[@b29-idr-9-035] USA                 2006--2009                    Retrospective               M-Staphylococcus and MRSA-select agar                                                                      Swabs from different anatomic sites on admission for culture and PCR on adults                                   12,456                                                                        3,137/12,456 (25.2%)                                           1,509/3,137 (48%)        1,628/3,137 (51.9%)     1,320/3,137 (42.1%)                                                             Groin/throat (89%)                                                                Nose/groin/throat (96%)

  Bitterman et al,[@b30-idr-9-035] Israel         2003--2006                    Retrospective               BBL CHROMagar MRSA                                                                                         Swabs from sites from ICU and non-ICU patients from screening sample (SS) and clinical diagnostic sample (CDS)   Not stated                                                                    359                                                            243/359 (67.7%)          117/359 (32.3%)         80/359 (22.2%)                                                                  Nares/perineum (89.6%)                                                            Nares/perineum/throat (93.6%)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** OX, Ofloxacin; FOX, cefoxitin; MRSA, methicillin-resistant *Staphylococcus aureus;* TID, theoretical isolation days; ICU, intensive care unit; HA, hospital associated; SSTI, skin and soft tissue infection; MICU, medical ICU; PCR, polymerase chain reaction.

###### 

Comparison of the prevalence of MRSA isolates detection between single nasal screening and nasal plus single extra-nasal or nasal plus multiple extra-nasal screening

  Stratification of studies by MRSA prevalence   MRSA prevalence (% \[CI\])   Proportion of MRSA detected by nasal screening (range)   Proportion of extra-nasal MRSA screening detected (range)   Proportion of MRSA to be missed without extra-nasal screening (range)   Proportion of nasal plus one site combination (range)   Proportion of nasal plus two extra-nasal sites combination (range)
  ---------------------------------------------- ---------------------------- -------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------- --------------------------------------------------------------------
  Low MRSA prevalence studies (≤6%)              3% (1.3--4.1)                75.1% (65--90)                                           37.6% (25--56.5)                                            23.7% (11--34)                                                          94% (88.9--100)                                         96.9% (95.7--98)
  High MRSA prevalence studies (≥6%)             16.3% (6.8--25.2)            64.6% (43.1--89.7)                                       46.4% (22.2--76)                                            26.8% (0.3--66)                                                         85.9% (62.5--100)                                       92.7% (81--100)
  All studies                                    12.2% (1.3--24)              68.2% (34--91)                                           47.6% (22.2--87.0)                                          21.4% (0.3--66)                                                         89.6% (62.5--100)                                       94.2% (81--100)

**Abbreviations:** MRSA, methicillin-resistant *Staphylococcus aureus;* CI, confidence interval.
